StockNews.com initiated coverage on shares of BIOLASE (NASDAQ:BIOL – Get Free Report) in a research note issued on Saturday. The brokerage set a “sell” rating on the medical technology company’s stock.
BIOLASE Price Performance
Shares of NASDAQ BIOL opened at $0.01 on Friday. The company has a 50 day simple moving average of $0.01 and a 200 day simple moving average of $0.01. The firm has a market cap of $451,996.71, a PE ratio of 0.00 and a beta of 0.67. BIOLASE has a 1 year low of $0.02 and a 1 year high of $1.94.
About BIOLASE
Further Reading
- Five stocks we like better than BIOLASE
- 5 Top Rated Dividend Stocks to Consider
- Archer Aviation’s Africa Deal Could Boost ACHR Stock
- How Can Investors Benefit From After-Hours Trading
- Are Short Sellers Wrong About These 3 Semiconductor Stocks?
- How to Know if a Stock Pays Dividends and When They Are Paid Out
- Boeing Gets $50B in March Orders—Is BA Stock a Buy Now?
Receive News & Ratings for BIOLASE Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BIOLASE and related companies with MarketBeat.com's FREE daily email newsletter.